Transaction #23549 · Form 4 · 0001231919-25-000644
Vor Biopharma Inc. · Stock award · Stock Option (Right to Buy)
Vor Biopharma Inc. · Transacted December 18, 2025 · Filed December 19, 2025
What does this filing report?
An SEC Form 4 filing for Vor Biopharma Inc. records a stock award involving Stock Option (Right to Buy) on December 18, 2025. The reported quantity was 3,000. The filing date is December 19, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- Vor Biopharma Inc.
- Company CIK
- 0001817229
- Security type
- Derivative
- Acquisition type
- Stock award · Code A
- Quantity acquired
- 3,000
- Reported price
- 0
- Reference value
- 0
- Currency
- Currency not specified
- Ownership
- Indirect
- Holdings after transaction
- 3,000
- Ownership description
- See Footnotes
- SEC acceptance time
- Dec 19, 2025, 6:58 PM EST
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- RA Capital Healthcare Fund LP ↗
Director · 10% owner
CIK 0001315082
- RA CAPITAL MANAGEMENT, L.P. ↗
Director · 10% owner
CIK 0001346824
- Kolchinsky Peter ↗
Director · 10% owner
CIK 0001384859
- Shah Rajeev M. ↗
Director · 10% owner
CIK 0001619841
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
This transaction is not mapped to a specific company listing.
Derivative terms
- Underlying security
- Common Stock
- Underlying quantity
- 3,000
- Conversion / exercise price
- 12.8
- Exercise date
- Not reported
- Expiration date
- December 17, 2035
Filing footnotes & remarks
- F1
- RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
- F2
- Held directly by the Fund.
- F3
- This option was granted to Dr. Andrew Levin pursuant to the Issuer's non-employee director compensation policy. The shares shall vest and become exercisable in a series of 36 successive equal monthly installments beginning on December 18, 2025, in each case subject to Dr. Levin's continued service as of each such date.
- F4
- Under Dr. Levin's arrangement with the Adviser, Dr. Levin holds the option for the benefit of the Fund. Dr. Levin is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock.
Remarks
Dr. Andrew Levin, a Partner and Managing Director of the Adviser, serves on the Issuer's board of directors.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.